Frovatriptan

Frovatriptan, a selective 5-HT1B/1D receptor agonist, is approved as an acute oral treatment for migraine headache and its associated symptoms. Frovatriptan was developed, commercialised, and brought to market by Vernalis.

 

Description

Frovatriptan is one of a class of prescription drugs called triptans, several of which are approved for the treatment of migraine.

Long half-life in the bloodstream

The key feature of frovatriptan is its exceptionally long blood half-life, which is in the region of 26 hours.

  • 5-HT1B/1D receptor agonist
  • Indicated for the acute treatment of migraine headache
  • Enjoys growing sales and market share

Background

As the first marketed product for Vernalis, frovatriptan was approved for the acute treatment of migraine in the EU in 2001 and in the United States in 2002, and remains on the market in these and other territories.
 
Despite the setback, in 2007, when frovatriptan failed to gain approval for the alternative indication of menstrual migraine it continues to sell well and is successfully marketed in many countries. It’s licensed to Menarini  for Europe, Central America and Brazil, and Vernalis earns royalties on sales in these territories. 

SK Chemicals holds the rights to the South Korean market (approved in 2009) and Vernalis receives royalties. 

Marketing rights in other areas of the world are still available.

Project Status

Menarini markets the product in Europe and Central America and plans further launches in these markets over the next few years.

During 2009, Vernalis had only limited economic interest in Menarini frovatriptan sales. But on 8th March 2010 (with effect from 1 January 2010), Vernalis regained 100% of the royalties receivable on Menarini’s sales by terminating agreements under which Paul Capital Healthcare had acquired an interest in 90 per cent of the Menarini royalty stream.

The composition of matter patent expired in December 2015.

Latest News

Servier and Vernalis plc announce achievement of 3 milestones in their oncology drug discovery collaboration

Servier and Vernalis plc are pleased to announce the achievement of two research milestones and one clinical milestone in their oncology drug discovery collaboration, triggering a total payment of €2 million to Vernalis.

 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch